Core Insights - The biopharmaceutical sector in Guangzhou, particularly in the Huangpu District, is rapidly developing, with a focus on innovation in areas such as gene therapy, diagnostics, and medical devices [1][5][21] - Guangzhou has established itself as a hub for unicorn companies, with 210 enterprises listed, 60 of which are in Huangpu, representing 29% of the city's total [1][5] - The "Strategic Entrepreneur Cultivation Plan" initiated by the Guangzhou Development Zone aims to enhance the competitiveness of biopharmaceutical companies through resource integration and systematic training [1][5] Biopharmaceutical Industry Development - Huangpu District has over 4,800 biopharmaceutical companies, including 528 high-tech firms and 21 listed companies, accounting for 72% of the city's total [7][21] - The district's industrial output value reached 35.1 billion yuan, positioning it among the top tiers of China's biopharmaceutical industry [7] - The area has seen a significant increase in clinical trial approvals, with 115 new approvals in 2024, including 99 for innovative drugs [7][21] Key Companies and Innovations - Yunzhou Biotech has become the world's largest CRO service provider for research-grade gene vectors, delivering over one million gene vectors globally by 2024 [2][17] - The company has achieved a compound annual growth rate of over 20% in revenue over the past three years, with a valuation exceeding 70 billion yuan, making it the first biopharmaceutical unicorn in Guangzhou [17] - Other notable companies in the region include Akeso, BeiGene, and Hengrui Medicine, contributing to a diverse and innovative biopharmaceutical landscape [5][18] Strategic Initiatives and Collaborations - The Guangzhou International Bio-Island initiative aims to create a comprehensive biopharmaceutical ecosystem through the establishment of pilot parks that enhance collaboration among companies [9][10] - The Huangpu District has implemented multiple policies to support the biopharmaceutical industry, including the "Biopharmaceutical 3.0" policy, which focuses on technology innovation, product commercialization, and talent support [25][30] - Recent investments from global healthcare giants, such as the establishment of a production base by Medtronic, highlight the area's attractiveness for foreign investment [28][30]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory, set to be implemented nationwide from January 1, 2026 [1][2] Summary by Sections National Medical Insurance Directory - A total of 114 new drugs have been added to the National Medical Insurance Directory, with 111 of them being new products launched within the last five years, representing 97.3% of the new additions [2] - Among the new drugs, 50 are classified as Category 1 innovative drugs, with a success rate of 88%, an increase from 76% in 2024 [2] - The total number of drugs in the directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [2] Company Announcements - Several listed companies, including Heng Rui Medicine, Fosun Pharma, and Hai Si Ke, announced new drug inclusions or renewals in the updated National Medical Insurance Directory [3] - Heng Rui Medicine reported that 20 products/indications were included, with significant coverage across various diseases such as tumors and cardiovascular conditions [3][4] - Hai Si Ke's two Category 1 innovative drugs were included, with one being a new addition and the other a renewal [4] Commercial Health Insurance Innovative Drug Directory - The first Commercial Health Insurance Innovative Drug Directory includes 19 new drugs from 18 innovative pharmaceutical companies, with 9 being Category 1 innovative drugs [7] - Notably, five CAR-T products were included, representing over half of the CAR-T products available in China, which previously faced challenges in entering the insurance market due to high pricing [7][8] - The directory also includes treatments for rare diseases and high-profile conditions such as Alzheimer's disease, enhancing the complementarity with the basic medical insurance [7][10] Notable Drug Inclusions - The directory includes drugs for significant diseases such as triple-negative breast cancer and pancreatic cancer, as well as treatments for rare diseases like Gaucher disease [5][9] - In the diabetes sector, several domestic drugs were newly included, such as a long-acting GLP-1 receptor agonist [6] - Companies like Bei Hai Kang Cheng and Bai Ji Shen Zhou have also successfully included their innovative drugs in the Commercial Health Insurance Directory [9]

Core Viewpoint - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, providing a dual-track system for basic and innovative drug coverage [1][2]. Group 1: National Medical Insurance Directory - A total of 114 new drugs have been added to the National Medical Insurance Directory, with 111 being new products launched within the last five years, representing 97.3% of the new entries [2]. - Among the new additions, 50 are classified as Class 1 innovative drugs, with an overall success rate of 88%, an increase from 76% in 2024 [2]. - The total number of drugs in the directory has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [2]. Group 2: Company Announcements - Several listed companies, including Heng Rui Medicine and Fuxing Medicine, announced new drug entries or renewals in the National Medical Insurance Directory [3]. - Heng Rui Medicine reported that 20 products/indications were included in the new directory, with a projected sales revenue of approximately 8.66 billion yuan in 2024 and about 7.55 billion yuan in the first three quarters of 2025 [4]. - Hai Si Ke's two Class 1 innovative drugs were also included, with applications in sedation and pain management [6]. Group 3: Commercial Health Insurance Innovative Drug Directory - The first Commercial Health Insurance Innovative Drug Directory includes 19 new drugs from 18 innovative pharmaceutical companies, with 9 being Class 1 innovative drugs [11]. - Notably, 5 CAR-T products were included, representing over half of the CAR-T products available in China, addressing previous challenges in pricing negotiations [11][12]. - The directory also includes treatments for rare diseases and high-profile conditions such as Alzheimer's disease, enhancing the coverage provided by basic medical insurance [11][13].

Core Points - The company has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and improve operational performance [1] - The total estimated sales for the included drugs in 2024 is approximately 8.66 billion yuan, and for the first three quarters of 2025, it is about 7.55 billion yuan [1] Drug Inclusion in National Medical Insurance Catalog - The following drugs have been newly included: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Zhumab - Sulfate of Amatuximab Tablets - Injection of Phosphorola Pitant Palonosetron - Injection of Ruikasi Zhumab - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following drugs have successfully added new indications: - Injection of Karelizumab - Fluorazepam Capsules - Injection of Fumaric Acid Tegafur [1] - The following drugs have been renewed and retained in the National Medical Insurance Catalog: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Methylsulfonylmethane Remazolam - Sulfate of Pevonedistat Injection [1] - The following drugs have new indications and have been adjusted to regular catalog management: - Mesylate of Apatinib Tablets - Lipid Injection of Bupivacaine [1] Impact on the Company - The inclusion of these drugs in the National Medical Insurance Catalog is expected to positively impact sales, although the exact effect on the company's operational performance is currently indeterminate [1] - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be announced by relevant government departments [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-194 江苏恒瑞医药股份有限公司关于公司药品纳入国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录 （2025年）》的通知（"《国家基本医疗保险、工伤保险和生育保险药品目录》"以下简称"国家医保目 录"），江苏恒瑞医药股份有限公司（以下简称"恒瑞医药"或"公司"）部分产品纳入国家医保目录。 通过医保谈判，注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊、夫那奇珠单抗注射液、硫酸艾玛昔替尼 片、注射用磷罗拉匹坦帕洛诺司琼、注射用瑞卡西单抗、醋酸阿比特龙片（Ⅱ）、盐酸伊立替康脂质体 注射液（Ⅱ）、瑞格列汀二甲双胍片（Ⅰ）/（Ⅱ）、全氟己基辛烷滴眼液首次纳入国家医保目录；注 射用卡瑞利珠单抗、氟唑帕利胶囊、富马酸泰吉利定注射液新增适应症成功纳入国家医保目录；马来酸 吡咯替尼片、海曲泊帕乙醇胺片、磷酸瑞格列汀片、注射用甲苯磺酸瑞马唑仑、硫培非格司亭注射液续 约成功保留在国家 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][6] Core Views - The company has shown rapid growth in performance, driven by innovation, with a significant increase in revenue and net profit in the first half of 2025 [4][9] - The company is increasing its research and development (R&D) investments, which are becoming a key growth engine, and is making progress in global expansion [4][6][9] Summary by Relevant Sections Financial Performance - In the first half of 2025, the company achieved revenue of RMB 15.761 billion, a year-on-year increase of 15.88% - The net profit attributable to shareholders was RMB 4.450 billion, up 29.67% year-on-year, while the adjusted net profit was RMB 4.273 billion, reflecting a growth of 22.43% [4][9] R&D and Innovation - The company invested a total of RMB 3.871 billion in R&D during the first half of 2025, with RMB 3.228 billion classified as expense R&D [4][9] - Six new innovative drugs were approved for market launch, contributing to over 60% of the company's revenue from innovative drug sales [9] Valuation and Earnings Forecast - The forecasted net profit for 2025-2027 is RMB 6.706 billion, RMB 7.978 billion, and RMB 9.208 billion respectively, with corresponding earnings per share (EPS) of RMB 1.01, RMB 1.20, and RMB 1.39 [6][8] - The price-to-earnings (P/E) ratios are projected to be 62.4x, 52.5x, and 45.4x for 2025, 2026, and 2027 respectively [6][8]

Investment Rating - The investment rating for the company is "Buy" [4][6]. Core Views - The company reported a strong performance in the first half of 2025, achieving revenue of 15.76 billion yuan (up 15.88%) and a net profit attributable to shareholders of 4.45 billion yuan (up 29.67%) [1][6]. - The company's international licensing achievements have significantly contributed to its revenue, with notable licensing agreements resulting in substantial upfront payments [2][3]. - The company has increased its R&D investment, totaling 3.87 billion yuan in the first half of 2025, which has driven rapid progress in its innovative pipeline [3]. Summary by Sections Financial Performance - In the first half of 2025, the company achieved operating revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit of 4.45 billion yuan, reflecting a growth of 29.67% [1][6]. - The net profit attributable to shareholders after deducting non-recurring items was 4.27 billion yuan, up 22.43% [1]. Licensing and Innovation - The company secured three significant licensing agreements in 2025, including a $200 million upfront payment from MSD and a $75 million payment from IDEAYA, which have bolstered its revenue [2]. - The innovative drug sales and licensing revenue reached 9.56 billion yuan, accounting for 60.66% of total revenue, with innovative drug sales alone contributing 7.57 billion yuan [3]. R&D and Product Pipeline - The company has accelerated its clinical pipeline, with six new Class 1 drugs approved for market and six new indications granted approval [3]. - As of the first half of 2025, the company had five applications accepted by NMPA, ten projects in Phase III clinical trials, and 22 projects in Phase II clinical trials [3]. Profit Forecast - The company is expected to achieve net profits of 8.65 billion yuan, 9.84 billion yuan, and 11.65 billion yuan for the years 2025, 2026, and 2027, respectively, with growth rates of 36.5%, 13.8%, and 18.3% [4].

Core Viewpoint - Heng Rui Medicine has demonstrated robust growth in its financial performance, with record-high revenue and profit figures, driven by a significant increase in innovative drug sales and a strategic shift towards innovation-focused business operations [1][2][4]. Financial Performance - In the first half of 2025, Heng Rui Medicine achieved operating revenue of 15.76 billion yuan, a year-on-year increase of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, reflecting a substantial growth of 29.67% [1]. - The net cash flow from operating activities reached 4.30 billion yuan, marking a 41.80% increase compared to the previous year [1]. Innovative Drug Growth - Innovative drug sales and licensing revenue reached 9.56 billion yuan, accounting for 60.66% of total operating revenue, with sales of innovative drugs alone amounting to 7.57 billion yuan [2]. - The proportion of innovative drug sales within the main business revenue (13.69 billion yuan) stands at 55.28%, indicating a significant shift from traditional generic drugs to innovative drugs [2]. R&D Investment and Achievements - Heng Rui Medicine has consistently increased its R&D investment, with expenditures of 6.35 billion yuan, 6.15 billion yuan, and 8.23 billion yuan from 2022 to 2024, representing 29.83%, 26.95%, and 29.40% of total revenue, respectively [4]. - As of the end of the reporting period, the cumulative R&D investment exceeded 48 billion yuan, supporting the company's long-term competitive advantage [4]. Globalization Strategy - The company has made significant strides in its globalization strategy, receiving upfront payments of 200 million USD from Merck and 75 million USD from IDEAYA for licensing agreements, contributing to revenue growth [7]. - Heng Rui Medicine has initiated over 20 overseas clinical trials and commercialized products in more than 40 countries, enhancing its global presence and influence [7].

Core Viewpoint - The global pharmaceutical market is witnessing a shift as Chinese innovative drugs transition from "followers" to "deep participants," with Heng Rui Medicine showcasing significant growth in its recent half-year report, highlighting a strategic acceleration in innovation and internationalization [1][10]. Financial Performance - Heng Rui Medicine reported a record high in both revenue and net profit for the first half of 2025, with total revenue reaching 15.761 billion yuan, a year-on-year increase of 15.88%, and net profit attributable to shareholders at 4.45 billion yuan, up 29.67% [1][2]. Innovation Drug Growth - The innovative drug segment saw substantial growth, with sales and licensing income amounting to 9.561 billion yuan, accounting for 60.66% of total revenue. Sales of innovative drugs alone reached 7.570 billion yuan, continuing a trend of growth [2][3]. Approval Milestones - In the first half of 2025, Heng Rui received approval for 12 innovative products, including 6 first-class innovative drugs, marking a significant acceleration in the approval process compared to previous years [3][4]. Business Structure Transformation - The business structure of Heng Rui has undergone a substantial transformation, with innovative drugs now serving as a new engine for growth rather than merely supplementary contributions. The company has established a robust pipeline with differentiated competitive advantages globally [4][10]. Internationalization Strategy - Heng Rui's internationalization strategy has evolved, focusing on opening new markets rather than just maintaining existing ones. The company has engaged in significant business development (BD) activities, including licensing agreements with major multinational corporations [6][7]. Collaborative Agreements - The company has entered into strategic collaborations, such as a partnership with GSK to co-develop up to 12 innovative drugs, which includes substantial upfront payments and potential milestone payments totaling around 12 billion USD [7][10]. Clinical Trials and Global Expansion - Heng Rui has initiated over 20 overseas clinical trials in various countries, including the U.S. and Europe, and has received orphan drug designation from the FDA for one of its innovative products, indicating a commitment to expanding its global research footprint [8][9]. Academic Recognition - The company has achieved significant academic recognition, with 173 important research results related to its products published in top-tier international journals, enhancing its global influence [9]. Talent Development - Heng Rui is focusing on talent acquisition and development, with a commitment to building a high-quality research team and enhancing its human resources strategy to support its innovation and internationalization goals [11][12]. Long-term Strategy - The long-term strategy emphasizes innovation, internationalization, and talent as key drivers for sustainable growth, positioning Heng Rui to transition from a domestic leader to a global competitor [13][14].

Core Viewpoint - 恒瑞医药 has entered a period of explosive growth, driven by strong revenue and profit increases, alongside significant investments in research and development [1][3]. Financial Performance - In the first half of 2025, 恒瑞医药 achieved operating revenue of 15.761 billion yuan, a year-on-year increase of 15.88% - Net profit attributable to shareholders reached 4.450 billion yuan, up 29.67% year-on-year - Operating cash flow net amount was 4.300 billion yuan, reflecting a 41.80% increase year-on-year [1]. Innovation and R&D - The company maintained high R&D investment, totaling 3.871 billion yuan in the first half of 2025, with 3.228 billion yuan classified as expense R&D [6]. - Six class 1 innovative drugs were approved for market entry during the reporting period, and the company has over 100 self-innovated products in clinical development [7]. - The innovative drug sales and licensing revenue reached 9.561 billion yuan, accounting for 60.66% of total revenue, with innovative drug sales alone contributing 7.570 billion yuan [3]. Licensing and Partnerships - The company has established external licensing as a normalized business, receiving significant upfront payments from partners such as Merck and IDEAYA, totaling 2 billion USD and 75 million USD respectively [3]. - A notable collaboration with GSK was formed to develop up to 12 innovative drugs, with an initial payment of 500 million USD and potential total payments reaching 12 billion USD [12]. Internationalization Efforts - 恒瑞医药 is accelerating its internationalization, having initiated over 20 overseas clinical trials in various countries [11]. - The company has received orphan drug designation from the FDA for its innovative drug, further enhancing its global presence [13]. Operational Management - The company is optimizing its organizational structure to enhance operational efficiency and sales performance, focusing on a dual-engine strategy of medical and market-driven sales [16]. - A global team of over 5,600 professionals is in place, with ongoing efforts to attract high-quality talent from top universities worldwide [17]. Recognition and Future Outlook - 恒瑞医药 has received multiple accolades, including being ranked second globally in self-research pipeline quantity and achieving an "AA" rating in MSCI ESG ratings [18]. - The company aims to continue its focus on innovation and internationalization, accelerating the development of competitive new drugs and expanding its global footprint [18].